MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte, Inc. (MXCT) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 5.78 M | -27,763,000 | 36.11 M | 268.27 M | 190.19 M |
| 2022 | 11.18 M | 5.03 M | 32.69 M | 286.65 M | 252.27 M |
| 2021 | 6.88 M | -42,100,300 | 21.22 M | 284.12 M | 270.43 M |
| 2020 | 5.17 M | -11,788,800 | 18.55 M | 51.78 M | 45.25 M |
| 2019 | 3.24 M | -7,999,500 | 16.38 M | 29.99 M | 24.45 M |